11:49 AM
 | 
Feb 15, 2019
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xtandi reduces radiographic PFS by 61% in metastatic hormone-sensitive prostate cancer

Astellas Pharma Inc. (Tokyo:4503) and Pfizer Inc. (NYSE:PFE) reported that Xtandi enzalutamide plus androgen deprivation therapy (ADT) reduced the risk of radiographic progression or death, the primary endpoint, by 61% vs. ADT alone in the Phase III ARCHES trial to treat metastatic hormone-sensitive prostate cancer (p<0.0001).

Median time to a radiographic progression-free survival (PFS) event in the Xtandi plus ADT arm was not reached; it was 19.4 months for the ADT alone arm.

Read the full 341 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >